Appointment comes as BPGbio plans for late-stage trials in oncology and rare disease

Dr. Modur brings over 25 years of experience as a drug developer

BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced the appointment of Vijay Modur, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Modur will continue to advance clinical trials for BPGbio and will join the BPGbio Leadership Team.

“It truly will be an honor and privilege to have Vijay as a colleague. He brings a wealth of experience and expertise in clinical development within the biotechnology and pharmaceutical industries, especially in oncology and rare disease sectors,” said Niven R. Narain, Ph.D., CEO and President of BPGbio. “BPGbio currently has five AI-guided and developed therapeutic assets in various stages of development, with potential considerations of an expanded Phase 3 asset. The addition of Dr. Modur to our leadership team will help us accelerate the translational medicine focus that is necessary to advance clinical assets to fill unmet needs to patients and families.”

Dr. Modur has had a remarkable career spanning multiple high-impact institutions, where he drove innovation, led successful turnarounds, and orchestrated strategic initiatives that have elevated the development of therapies for rare and complex diseases. Prior to joining BPGbio, Dr. Modur served as Head of Research and Development at Eloxx Pharmaceuticals. Before that he was the Chief Scientific and Medical Officer at Zikani Therapeutics. Earlier in his career, he held a variety of leadership positions with Sanofi-Genzyme, HTG Molecular Diagnostics, Novartis Diagnostics, Novartis Oncology, and Merck & Co., Inc. Dr. Modur received his MBBS at Karnatak University, Dharwad, India, and his Ph.D. in experimental pathology at the University of Utah. He completed his residency training in the Department of Pathology and Laboratory Medicine at Washington University in St. Louis.

“Artificial intelligence is revolutionizing traditional drug discovery and I’m thrilled to be part of BPGbio, which is at the forefront of using AI to harness the power of biology for a healthier tomorrow,” said Dr. Modur. “I’m excited about the deep therapeutics and diagnostic pipeline BPGbio has, particularly those in late clinical stages, and I am looking forward to working with the BPGbio team to advance and commercialize our pipeline to help patient communities with unmet medical needs.”

BPGbio’s therapeutic pipeline includes therapeutic candidates being studied for glioblastoma multiforme (GBM), pancreatic cancer, EB, SCC, sarcopenia, solid and liquid tumors, Huntington’s disease, Parkinson's disease, and mitochondria-related disease. The company's diagnostic pipeline includes its prostate diagnostic panel, the pstateDx™ test, which has been launched in Mexico, as well as tests being developed and validated for the detection of Parkinson's disease, pancreatic cancer, breast cancer, and liver disease.

BPGbio offers its sincere gratitude to Brian Berman, M.D., Ph.D., who has served as Acting CMO for over 10 months.

About BPGbio, Inc.

BPGbio is a leading AI-powered clinical stage biopharma and diagnostics company focused on oncology, neurology, and rare diseases. The company has a deep portfolio of AI-developed pipeline of therapeutics, including several in late-stage development. BPGBio’s novel approach is underpinned by NAI, its proprietary Interrogative Biology Platform, protected by over 400 US and international patents; the world's largest clinically annotated non-governmental biobank; and exclusive access to the most powerful supercomputer in the world. With these tools, BPGbio is redefining how patient biology can be modeled using unbiased AI. Headquartered in Boston, the company is at the forefront of a new era in medicine, combining biology, data, and AI to transform the way we understand aging, human performance, and diagnose and treat disease. For more information, visit bpgbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231002411883/en/